These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24059336)

  • 1. Therapy in prion diseases.
    Forloni G; Artuso V; Roiter I; Morbin M; Tagliavini F
    Curr Top Med Chem; 2013; 13(19):2465-76. PubMed ID: 24059336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutics for prion diseases].
    Doh-ura K
    Rinsho Shinkeigaku; 2003 Nov; 43(11):820-2. PubMed ID: 15152474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells.
    Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
    PLoS One; 2014; 9(9):e106516. PubMed ID: 25181483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current Trends in the Treatment of Prion Disease].
    Tsuboi Y
    Brain Nerve; 2015 Jul; 67(7):941-6. PubMed ID: 26160821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systematic review of the therapeutics for prion diseases].
    Sakaguchi S
    Brain Nerve; 2009 Aug; 61(8):929-38. PubMed ID: 19697882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights from Therapeutic Studies for PrP Prion Disease.
    Teruya K; Doh-Ura K
    Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 27836910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?
    Rainov NG; Tsuboi Y; Krolak-Salmon P; Vighetto A; Doh-Ura K
    Expert Opin Biol Ther; 2007 May; 7(5):713-26. PubMed ID: 17477808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases.
    Larramendy-Gozalo C; Barret A; Daudigeos E; Mathieu E; Antonangeli L; Riffet C; Petit E; Papy-Garcia D; Barritault D; Brown P; Deslys JP
    J Gen Virol; 2007 Mar; 88(Pt 3):1062-1067. PubMed ID: 17325382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones.
    Kamatari YO; Hayano Y; Yamaguchi K; Hosokawa-Muto J; Kuwata K
    Protein Sci; 2013 Jan; 22(1):22-34. PubMed ID: 23081827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human prion protein fragment 90-231, a useful model to study prion neurotoxicity.
    Corsaro A; Thellung S; Villa V; Nizzari M; Aceto A; Florio T
    OMICS; 2012; 16(1-2):50-9. PubMed ID: 22321015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease-resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion.
    Honda H; Sasaki K; Minaki H; Masui K; Suzuki SO; Doh-Ura K; Iwaki T
    Neuropathology; 2012 Apr; 32(2):124-32. PubMed ID: 21801238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thienyl pyrimidine derivatives with PrP(Sc) oligomer-inducing activity are a promising tool to study prions.
    Imberdis T; Ayrolles-Torro A; Verdier JM; Perrier V
    Curr Top Med Chem; 2013; 13(19):2477-83. PubMed ID: 24059332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular vesicles with diagnostic and therapeutic potential for prion diseases.
    Khadka A; Spiers JG; Cheng L; Hill AF
    Cell Tissue Res; 2023 Apr; 392(1):247-267. PubMed ID: 35394216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches for the selection and evaluation of anti-prion organic compounds.
    Cordeiro Y; Ferreira NC
    Mini Rev Med Chem; 2015; 15(2):84-92. PubMed ID: 25723455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting interactions between prion protein isoforms.
    Caughey B; Baron GS
    Biochem Soc Trans; 2002 Aug; 30(4):565-9. PubMed ID: 12196138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Innovation of therapeutics and prophylaxis for prion diseases].
    Doh-ura K
    Rinsho Shinkeigaku; 2009 Nov; 49(11):946-8. PubMed ID: 20030256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.
    Wong C; Xiong LW; Horiuchi M; Raymond L; Wehrly K; Chesebro B; Caughey B
    EMBO J; 2001 Feb; 20(3):377-86. PubMed ID: 11157745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous quinacrine treatment results in the formation of drug-resistant prions.
    Ghaemmaghami S; Ahn M; Lessard P; Giles K; Legname G; DeArmond SJ; Prusiner SB
    PLoS Pathog; 2009 Nov; 5(11):e1000673. PubMed ID: 19956709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
    Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
    Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?
    Caughey B; Caughey WS; Kocisko DA; Lee KS; Silveira JR; Morrey JD
    Acc Chem Res; 2006 Sep; 39(9):646-53. PubMed ID: 16981681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.